{
    "pmcid": "7473855",
    "qa_pairs": {
        "How was the nanobody Ty1 identified and characterized?": [
            "Through phage display and next-generation sequencing after immunizing an alpaca.",
            "By screening a human antibody library using yeast display technology.",
            "By isolating antibodies from convalescent COVID-19 patients.",
            "Through computational modeling and in silico docking studies."
        ],
        "What advantage does Ty1 have over conventional antibodies in terms of production?": [
            "It can be produced in large quantities in bacterial systems, making it cost-effective and scalable.",
            "It requires mammalian cell culture for expression, ensuring high fidelity.",
            "It can only be synthesized chemically, allowing for precise modifications.",
            "It needs to be produced in insect cell systems for proper folding."
        ],
        "What is the primary mechanism by which the alpaca-derived nanobody Ty1 neutralizes SARS-CoV-2?": [
            "By blocking the interaction between the RBD of the spike protein and the ACE2 receptor.",
            "By degrading the viral RNA genome inside host cells.",
            "By binding to the nucleocapsid protein and preventing viral assembly.",
            "By inhibiting the viral protease necessary for protein processing."
        ],
        "What potential modification could enhance the therapeutic properties of Ty1?": [
            "Creating multimeric forms or fusions with Fc domains to improve serum half-life and avidity.",
            "Increasing its size to improve binding surface area.",
            "Reducing its affinity to allow for reversible binding.",
            "Adding glycosylation sites to increase stability."
        ],
        "What structural feature of the SARS-CoV-2 spike protein does Ty1 target to prevent viral entry?": [
            "The receptor-binding domain (RBD).",
            "The fusion peptide region.",
            "The transmembrane domain.",
            "The S2 subunit."
        ]
    }
}